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1. Introduction
Hepatocellular carcinoma (HCC) is a primary malignant tumor of the liver which represents
a serious public health problem in the world, corresponding to the fifth more frequent
malignant neoplasia among men, the eighth among women, and the third cause of cancer death
in the world [1,2]. Seventy to ninety percent of HCC cases occur in patients with cirrhosis or
with chronic liver disease, with cell injury followed by regeneration mediated by the immune
response playing an important role in hepatocarcinogenesis [3].
In Brazil, a national survey to update HCC epidemiology and clinical profile of patients with
HCC (29 centers, with 1,405 patients diagnosed with HCC from 2004 to 2009) showed that the
median age at diagnosis was 59 years (1–92 years old; 78% male) and 98% of the patients had
cirrhosis (1279/1308), with the hepatitis C virus being the main etiology (54%), followed by
hepatitis B virus (16%) and alcohol (14%). In Southeastern and Southern Brazil, hepatitis C
virus accounted for over 55% of cases. In the Northeast and North, hepatitis C virus accounted
for less than 50%, and hepatitis B virus accounted for 22–25% of cases [4]. In Ribeirão Preto,
Southeastern Brazil, the clinical characteristics of 130 patients with HCC attended at the
University Hospital of the Faculty of Medicine of Ribeirao Preto, University of São Paulo
(HCFMRP-USP) was revised. The mean (± SD) age at the time of HCC diagnosis was 55.6±11.2
years, with 81.5% of them being males. Cirrhosis was present in 89.2% of cases, with 53.4% of
© 2013 Teixeira et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
the patients being ChildPugh A; chronic hepatitis B or C without cirrhosis was detected in
3.2%, nonalcoholic steatohepatitis (NASH) in 3.8%, and a normal liver in 3.8% [5].
The human major histocompatibility complex (MHC) represents a set of genes responsi‐
ble for coding histocompatibility molecules. It is a high density region [3.6 Mb DNA) located
on the short  arm of  chromosome 6,  region 6p21.3,  which contains more than 200 genes
grouped into three classes denoted class I, II and III. Class I genes (classic or class Ia) code
for the classic histocompatibility molecules HLA-A, B and C; class II  genes code for the
histocompatibility molecules HLA-DR, DQ and DP, and class III genes, although includ‐
ed in the MHC, do not code for histocompatibility molecules. Among class I genes, there
are also those denoted non-classic or class Ib, which code for the non-classic histocompat‐
ibility molecules HLA-E, F and G [6].
HLA-G is a class I non-classic HLA gene consisting of eight exons and seven introns with
a stop codon in exon 6 (exon 7 is always absent from mature mRNA and, due to the stop
codon in exon 6, exon 8 is not translated), a 5’ promoter region and a 3’ untranslated region
(3’UTR) [7,8]. The characteristics of HLA-G are: low polymorphism, alternative splicing in
the primary transcript that codes for seven protein isoforms, limited distribution in normal
tissues, and immunsuppressive properties [9]. Of the seven proteins coded by the HLA-G
gene, four are linked to the membrane (HLA-G1 to HLA-G4) and three are soluble (HLA-
G5 to HLA-G7).  The HLA-G1 and HLA-G5 proteins are the main isoforms described in
healthy issues such as trophoblast, thymus, cornea, and erythroid and endothelial precur‐
sors.  On the other hand, the expression of HLA-G  can be induced in pathological  situa‐
tions  such  as  autoimmune  and  inflammatory  diseases,  viral  infections,  cancer,  and
transplantation. HLA-G exerts inhibitory activity by binding to inhibitory receptors denoted
immunoglobulin-like transcript (ILT)-2 and ILT-4, which are expressed by lymphoid and
myeloid  cells  and  by  myeloid  cells  only,  respectively,  and  killer  immunoglobulin-like
(KIR)2DL4 receptor, present only in natural killer cells [9].
Thus far, 47 alleles have been attributed to the HLA-G gene, which code for 15 distinct
functional proteins with all isoforms (HLA-G*01:01, *01:02, *01:03, *01:04, *01:06, *01:07, *01:08,
*01:09, *01:10, *01:11, *01:12, *01:14, *01:15, *01:16, and *01:17) and truncated (G*01:05N allele)
or no proteins at all (G*01:13N allele). Polymorphic sites are observed in the coding and non-
coding regions. The promoter and 3´UTR regions of HLA-G are highly polymorphic, with the
variations in the 3´UTR being associated with the levels of HLA-G expression. Two main
polymorphic sites were identified in the 3´UTR: a 14bp insertion/deletion, in which the
insertion has been associated with reduced levels of HLA-G, and the presence of guanine at
position +3142, which increases the affinity of specific microRNAs for HLA-G mRNA, reducing
the expression of HLA-G [8,10].
The expression of HLA-G is frequently detected in malignant tumors of various origins and in
some situations has been significantly correlated with tumor size, degree of invasion, meta‐
stasis, clinical stages of the disease, and mortality [11,12]. Regarding HCC, few studies
evaluating the role of alleles and genotypes of HLA-G polymorphism are available in the
literature, and evolve different population. Jiang et al, studying a Chinese population showed
that the heterozygote and the 14bp II homozygote confer a lower risk of HCC compared with
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14bp DD, and that the associations were stronger in the hepatitis B-positive than the hepatitis
B-negative population [13] Zhang et al, examining fifteen single-nucleotide polymorphisms
(SNPs) in the non-classical class I alleles, found that the SNPs rs17875380, rs41557518,
rs114465251, and rs115492845 were associated with susceptibility to chronic hepatitis B
infection or HCC, and HLA-F*01:04, HLA-G*01:05N, and HLA-E*01:01 were associated with
hepatitis B or hepatitis B with HCC [14].
In general, the inflammatory response mediated by the immune system is beneficial to the
host; however, when tissue homeostasis is chronically affected the interactions between innate
and adaptive immune responses may be deregulated, culminating with chronic inflammation,
excessive tissue remodeling, loss of tissue architecture, apoptosis/necrosis and oxidative stress
which, under certain circumstances, may increase the risk of tumor development [15]. The
cytokines are responsible for the regulation of growth differentiation and activation of immune
cells. The ability to produce cytokines by an individual is influenced by genetic components
that have been attributed to molecular mechanisms, including variations in the transcription,
translation and secretion pathways [16].
2. Problem statement
Over the last years, regarding HCC, few studies evaluating the role of alleles and genotypes
of HLA-G polymorphism are available in the literature, and included diverse patient popula‐
tions. Moreover, previous studies have concentrated on cytokine promoters, encouraged by
the identification of a series of SNPs [17]. However, the relation of these polymorphisms with
susceptibility to HCC or disease severity has not been clarified.
Application area
Immune response and carcinogenesis
Research course
Alleles and genotypes of cytokines polymorphisms and 14bp of HLA-G gene in HCC patients.
3. Method and patients
We evaluated, in a Brazilian cohort, the association of alleles and genotypes of the 14bp
insertion/deletion polymorphism of the HLA-G gene, and alleles and genotypes of polymor‐
phisms of genes IL-18 (-607 C/A; rs1946518 and -137 C/G; rs187238), IFN-γ (+874 A/T;
rs62559044) and TNF-α (-238 A/G; rs361525 and -308 A/G; rs1800629) with susceptibility to
HCC and with the type of tumor presentation (infiltrative diffuse, multinodular and uninod‐
ular), with nodule size (>10 cm, 5-10 cm and <5 cm), with the Milan criteria (fulfills or does not
fulfill), the evaluation of metastasis (present or absent), and the histological classification of
the tumor (Edmondson-Steiner Classification) [18,19, 20,21].
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This was a retrospective cross-sectional study conducted on 109 patients (89 men) with mean
age 55.8±11.4 years for the 14bp insertion/deletion polymorphism of the HLA-G gene, and 112
consecutive patients [Mean (±SD) age was 55.6±11.2 years, and 81.5% were males] for the
polymorphisms of genes IL-18 (-607 C/A; rs1946518 and -137 C/G; rs187238), IFN-γ (+874 A/T;
rs62559044) and TNF-α (-238 A/G; rs361525 and -308 A/G; rs1800629) followed up from 2001
to 2009 at the Focal Hepatic Injuries Outpatient Clinic of the Faculty of Medicine of Ribeirão
Preto, University of São Paulo (HCFMRP-USP). The study was approved by the Research
Ethics Committee of HCFMRP-USP. Individuals of both genders who fulfilled the following
criteria were included in the study: a) diagnosis of HCC defined by the Barcelona 2000 criteria
[22] for the diagnoses performed up to 2006 and according to the recommendations of the
American Association for the Study of Liver Disease (AASLD) [23] for the diagnoses performed
since 2007; b) with DNA stored in the Biological Sample Bank of the Laboratory of Gastroen‐
terology, Department of Internal Medicine. Exclusion criteria were patients with focal hepatic
injuries other than HCC according to the Barcelona 2000 criteria and the recommendations of
the AASLD and patients with other concomitant neoplasias.
The evaluation of the severity of HCC was based on: a) tumor presentation (uninodular,
multinodular or diffuse infiltrative); b) nodule size (<5 cm, 5-10 cm or >10 cm); c) Milan criteria
(fulfills or does not fulfill); d) metastasis (present or absent); e) histological classification
according to Edmondson & Steiner, 1954 (grades I, II, III or IV) [24].
A total of 202 healthy individuals (56 females and 146 males) with a mean age (±SD) of 33.3±8.3
years and from the same geographic region as the patients studied were used as controls for
the evaluation of the frequency of 14bp, IL-18, IFN-γ and TNF-α alleles and genotypes.
For the determination of the 14bp insertion/deletion, IL-18 (-607 C/A; rs1946518 and -137 C/G;
rs187238), IFN-γ (+874 A/T; rs62559044) and TNF-α (-238 A/G; rs361525 and -308 A/G;
rs1800629) genotypes, we first extracted genomic DNA from peripheral leukocytes by the
salting out technique [25]. The HLA-G 14bp insertion/deletion genotypes at exon 8 of the HLA-
G locus was analyzed as described: 200ng of genomic DNA were amplified in a 25mL reaction
mixture containing 0.20mM dNTP (Invitrogen, Carlsbad, CA), 0.2mM of each primer, 0.5U
Taq DNA polymerase (Invitrogen, Carlsbad, CA), 1.5mM MgCl2 and a 1x PCR buffer (0.2M
Tris–HCl, pH 8.5; 0.5M KCl). After an initial denaturation step at 94°C for 5 minutes, samples
were submitted to 30 additional cycles at 94°C for 45 seconds, 56°C for 45 seconds and 72°C
for 1 minute, with a final extension cycle at 72°C for 7 minutes with 5´-TGTGAAA‐
CAGCTGCCCTGTG-3´ as the forward primer and 5´-AAGGAATGCAGTTCAGCATGA-3´ as
the reverse primer [26,27]. After DNA amplification by PCR, the reaction products were
submitted to 10% polyacrylamide gel electrophoresis under non-denaturing conditions
followed by silver impregnation. The presence of 345 bp fragments corresponded to the
deletion allele, while the 359 bp fragment corresponded to the 14bp insertion allele.
The alleles and genotypes of IL-18 (-607 C/A; rs1946518 and -137 C/G; rs187238), IFN-γ (+874
A/T;  rs62559044)  and  TNF-α  (-238  A/G;  rs361525  and  -308  A/G;  rs1800629)  polymor‐
phisms were analyzed by the polymerase chain reaction using allele-specific primers (PCR-
SSP)  (Table  1).  For  SNP  IL-18  −607,  a  generic  reverse  primer  5′-TAACCTCATTCAGG
Hepatocellular Carcinoma - Future Outlook4
ACTTCC-3′ and two allele-specific forward primers (5′-GT TGCAGAAAGTGTAAAAAT‐
TATTAC-3′ and 5′-GTTGCAG AAAGTGTAAAAATTATTAA-3′) were used to amplify a
196-bp product. For SNP IL-18 −137, a common reverse primer 5′-AGGAGGGCAAAATG‐
CACTGG-3′  and  two  allele-specific  forward  primers  (5′-CCCCAACTTTTACGGAAG
AAAAG-3′  and 5′-CCCCAACTTTTACGGAAGAAAAC-3′)  were  used  to  amplify  a  261-
SNP Primer Sequence (5’-3’)
IL-18 -607 C/A IL-18 607.2 TAACCTCATTCAGGACTTCC
IL-18 607C GTTGCAGAAAGTGTAAAAATTATTAC
IL-18 607A GTTGCAGAAAGTGTAAAAATTATTAA
HGBA.S CGGTATTTGGAGGTCAGCAC
HGBA.A CCCACCACCAAGACCTACTT
IL-18 -137 C/G IL-18 137.2 AGGAGGGCAAAATGCACTGG
IL-18 137C CCCCAACTTTTACGGAAGAAAAC
IL-18 137G CCCCAACTTTTACGGAAGAAAAG
HGBA.S CGGTATTTGGAGGTCAGCAC
HGBA.A CCCACCACCAAGACCTACTT
IFN-γ +874 A/T IFN-γ 874
IFN-γ 874 T
IFN-γ 874 A
TCAACAAAGCTGATACTCCA
TTCTTACAACACAAAATCAAATCT
TTCTTACAACACAAAATCAAATCA
GH 1 GCCTTCCCAACCATTCCCTTA
GH 2 TCACGGATTTCTGTTGTGTTTC
TNF-α -238 A/G TNF 238 UP AGGCAATAGGTTTTGAGGGCCAT
TNFAS238G CCCCATCCTCCCTGCTCC
TNFAS238A TCCCCATCCTCCCTGCTCT
HGBA.S CGGTATTTGGAGGTCAGCAC
HGBA.A CCCACCACCAAGACCTACTT
TNF-α -308 A/G TNFAA 308.2 CAGCGGAAAACTTCCTTGGT
TNFAS 308G ATAGGTTTTGAGGGGCATGG
TNFAS 308A ATAGGTTTTGAGGGGCATGA
HGBA.S CGGTATTTGGAGGTCAGCAC
HGBA.A CCCACCACCAAGACCTACTT
IL-18: interleukin-18; IFN-γ: interferon-gamma; TNF-α: tumor necrosis factor-alpha; HGBA.S and HGBA.A: human
hemoglobin; GH1 and GH2: human growth hormone.
Table 1. Primers for the detection of single nucleotide polymorphisms (SNPs) of genes IL-18 (-607 C/A and -137 C/G),
IFN-γ (+874 A/T) and TNF-α (-238 A/G and -308 A/G).
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bp product. An internal positive amplification control was performed using the primers 5′-
CG GTATTTGGAGGTCAGCAC-3′ and 5′-CCCACCACCAAGA CCTACTT-3′,  which are
specific  for  the  human hemoglobin genes.  The reactions  were  performed in  a  final  vol‐
ume of 10μL containing 200ng of genomic DNA, 3pmol of each primer (the generic one
and a specific one), 2pmol of each control primer, 0.25mM dNTP (Pharmacia Biotech, Paris,
France), 1.5mM MgCl2, 0.75U of Taq DNA poly- merase (Invitrogen, Carlsbad, CA), and
1× PCR buffer (0.2 M Tris – HCl, pH 8.5, 0.5 M KCl). The cyclingconditions were 3min at
94°C, followed by seven cycles of 20s at 94°C, 40s at 64°C for IL18 -607 or 60s at 68°C for
IL18 -137 and 40s at 72°C and 25 cycles of 20s at 94°C, 40s at 57°C for IL18 -607 or 20s at
62°C for IL18 -137 and 40s at 72°C, and final stage of 5min at 72°C [9]. For the TNF-α (-238
and  -308)  and  IFN-γ  +874  specific  amplification,  the  primers  were  identical  to  those
previously described [28,29].  All  amplification products were visualized using 10% non-
denaturing polyacrylamide gel electrophoresis (PAGE) followed by silver staining.
For statistical analysis, the allele and genotype frequencies were calculated by the direct count
method in all groups. Adherence of genotypic proportions to Hardy-Weinberg expectations
was determined by the exact test of Guo and Thompson [30] using the GENEPOP software v.
4.0.10. The presence of a significant association between polymorphisms of the same gene was
evaluated by a likelihood ratio test of probability of linkage disequilibrium using the ARLE‐
QUIN software, v. 3.1 [31]. If a positive association was detected, but the gameteic phase was
unknown, the PHASE (v. 2 package) [32] and EM algorithms [33] were used to reconstruct the
TNF or IL haplotypes. Allele, genotype and haplotype frequencies were compared by the two-
tailed Fisher exact test using the GraphPad InStat 3.06 software, which was also used to
estimate the odds ratio (OR) and its 95% confidence interval (95%CI). The level of significance
was set at P<0.05.
4. Results
Cirrhosis  was  observed  in  89%  of  the  patients,  and  major  underlying  causes  included:
hepatitis C (35%), alcohol plus hepatitis C (25%), alcohol (18%), hepatitis B (9%), alcohol
plus hepatitis B (4%), alcohol plus hepatitis C plus hepatitis B (1%), hereditary hemochro‐
matosis (1%), non-alcoholic steatohepatitis (1%), autoimmune hepatitis (1%) and cryptogen‐
ic  cirrhosis  (5%).  Four percent of  the patients  had no underlying liver disease,  4% non-
alcoholic  steatohepatitis  and 3% chronic hepatitis  without cirrhosis  (two hepatitis  B and
one hepatitis C). Fifty-four percent (59/109) of the patients met the Milan criteria for liver
transplantation [34]. Metastasis search was performed in 88% of cases (17% had metasta‐
sis and 93% did not). Tumors <5cm, 5-10cm and >10 cm were found in 57%, 18% and 8%
respectively. Diffuse infiltrative HCC totaled 15% of the cases. Histological evaluation of
HCC was performed in 39% (42/109) of subjects with 62% presenting Edmondson-Steiner
I or II and 38% III or IV.
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4.1. 14bp insertion/deletion polymorphism
Genotype frequencies of patient and control groups were in accordance to Hardy-Weinberg
Equilibrium. The 14bp*D allele was more frequent in cases of HCC than in controls (0.6514 vs.
0.5619; P=0.0326), conferring an OR=1.46 (95%CI=1.04-2.05). Evaluation of genotype frequency
(genotypes 14pb DD, DI and II) did not show significant difference between the groups studied
(P=0.0871; OR=1.54; 95%CI=0.96-2.48; P=0.7182; OR=0.89; 95%CI=0.56-1.44; and P=0.1343;
OR=0.60; 95%CI=0.32-1.12, respectively). However, the 14bp DD genotype was marginally
more frequent among individuals with HCC than among controls, with 10.3% difference
(0.4495 vs. 0.3465, respectively) (P=0.0871; OR=1.54; 95%CI=0.96-2.48). Patients were stratified
according to the characteristics of HCC (type of tumor presentation, nodule size, Milan criteria,
presence of metastasis and Edmondson-Steiner classification), and no significant differences
were detected between groups regarding the 14bp insertion/deletion allele frequencies
(14bp*D and 14bp*I alleles) or genotype frequencies (14bp DD, DI and II genotypes). Table 2
shows the frequency of the 14bp insertion/deletion polymorphism and Table 3 shows the
results of the statistical analyses.
Samples 14bp alleles 14bp genotypes
I D II DI DD
Groups n(frequency) n(frequency) n(frequency) n(frequency) n(frequency)
Control 177 [0.4381] 227 [0.5619] 45 [0.2228] 87 [0.4307] 70 [0.3465]
HCC 76 [0.3486] 142 [0.6514] 16 [0.1468] 44 [0.4037] 49 [0.4495]
Tumor presentation
Diffuse 7 [0.2500] 21 [0.7500] 1 [0.0714] 5 [0.3571] 8 [0.5714]
Multinodular 14 [0.3684] 24 [0.6316] 13 [0.1579] 9 [0.4211] 6 [0.4211]
Uninodular 55 [0.3667] 95 [0.6333] 12 [0.1600] 31 [0.4133] 32 [0.4767]
Nodule size
>10cm 6 [0.3333] 12 [0.6667] 1 [0.1111] 4 [0.4444] 4 [0.4444]
5-10cm 11 [0.2750] 29 [0.7250] 1 [0.0500] 9 [0.4500] 10 [0.5000]
<5cm 51 [0.4113] 73 [0.5887] 13 [0.2097] 25 [0.4032] 24 [0.3871]
Metastasis
Present 4 [0.2857] 10 [0.7143] 0 [0.0000] 4 [0.5714] 3 [0.4286]
Absent 63 [0.3539] 115 [0.6461] 13 [0.1461] 37 [0.4157] 39 [0.4382]
Milan criteria
Yes 46 [0.3898] 72 [0.6102] 11 [0.1864] 24 [0.4068] 24 [0.4068]
No 30 [0.3000] 70 [0.7000] 5 [0.1000] 20 [0.4000] 25 [0.5000]
Edmondson
I-II 24 [0.4615] 28 [0.5385] 5 [0.1923] 14 [0.5385] 7 [0.2692]
III-IV 16 [0.5000] 16 [0.5000] 4 [0.2500] 8 [0.5000] 4 [0.2500]
HLA-G: Human Leukocyte Antigen-G; bp: base pairs; HCC: hepatocellular carcinoma; I: insertion; D:deletion
Table 2. Distribution of the HLA-G 14bp insertion/deletion allele and genotype frequencies.
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Comparisons 14bp alleles 14bp genotypes
I D II DI DD
Groups
HCC vs. control 0.0326 0.0326a 0.1343 0.7182 0.0871b
Tumor presentation
Diffuse vs. multinodular 0.4238 0.4238 0.6197 1,0000 0.4905
Diffuse vs. uninodular 0.2839 0.2839 0.6830 0.7738 0.3863
Multinodular vs. uninodular 1.0000 1.0000 1.0000 1.0000 1.0000
Nodule size
>10 cm vs. 5-10 cm 0.7577 0.7577 0.5320 1.0000 1.0000
>10 cm vs. <5 cm 0.6132 0.6132 0.6769 1.0000 0.7318
5-10 cm vs. <5 cm 0.1372 0.1372 0.1698 0.7963 0.4382
Milan criteria
Yes vs. no 0.1995 0.1995 0.2794 1.0000 0.3421
Metastasis
Present vs. Absent 0.7739 0.7739 0.5883 0.4556 1.0000
Edmondson-Steiner
I-II vs. III-IV 0.8232 0.8232 0.7109 1.0000 1.0000
HLA-G: Human Leukocyte Antigen-G; bp: base pairs; HCC: hepatocellular carcinoma; I: insertion; D:deletion
a Odds ratio= 1.46 [95% confidence interval: 1.04-2.05]
b Odds ratio= 1.54 [95% confidence interval: 0.96-2.48]
Table 3. Probability values obtained by means of two-tailed Fisher exact test in the comparisons of HLA-G 14bp
insertion/deletion allele and genotype frequencies between different groups.
4.2. IL-18 (-607 C/A; rs1946518 and -137 C/G; rs187238), IFN-γ (+874 A/T; rs62559044) and
TNF-α (-238 A/G; rs361525 and -308 A/G; rs1800629) polymorphism
The genotypification of the polymorphisms of the genes IL-18 (-607 C/A and -137 C/G), IFN-γ
(+874 A/T) and TNF-α (-238 A/G and -308 A/G) was performed in 112 patients with HCC and
in 202 healthy controls. The genotype distribution of the two groups adhered to the theoretical
proportions of Hardy-Weinberg equilibrium. Significant associations were detected between
HCC and the following alleles (Table 4): IL-18 -607*A (P=0.0235; OR=1.48; 95%CI=1.06-2.08);
TNF-α -238*A (P=0.0025; OR=2.12; 95%CI=1.32-3.40), and TNF-α -308*A (P=0.0351; OR=1.82;
95%CI=1.07-3.08). When the genotypes were evaluated (Table 5), the following associations
with HCC were detected: IL-18 -607 AA (P=0.0048; OR=3.03; 95%CI=1.40-6.55); TNF-α -238 GA
(P=0.0011; OR=2.44; 95%CI=1.45-4.12); and TNF-α -308 GA (P=0.0031; OR=2.51;
95%CI=1.39-4.51). Alleles and genotypes from IL-18 -137G/C and IFNγ +874T/A were not
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associated with susceptibility to HCC. The inference of haplotypes was performed for the
polymorphisms of IL-18 and TNF-α. Haplotypes -607A/-137G IL-18 and TNF-α -308G/-238A
-308A/-238G were more frequent in patients with HCC compared with the control group (P =
0.0180, OR = 1.69, 95% CI 1.10 to 2.59, P = 0.0036, OR = 2.06, 95% CI 1,28-3.31 and P = 0.0480,
OR = 1.75; 95% CI = 1.03 to 2.97, respectively). On the other hand, TNF-α -308G/-238G haplotype
was more frequent in the group of healthy subjects (P = 0.0001, OR = 0.46, 95% CI 0.32 to 0.68),
providing protection against HCC.
SNP Allele frequency
allele HCC
n (frequency)
Control
n (frequency)
P OR 95%CI
IL-18 -137C/G C 62 [0.2768] 120 [0.2970] 0.6464 0.90 0.63-1.30
G 162 [0.7232] 284 [0.7030] 0.6464 1.10 0.77-1.59
IL-18 -607A/C A 92 [0.4107] 129 [0.3193] 0.0235 1.48 1.06-2.08
C 132 [0.5893] 275 [0.6807] 0.0235 0.67 0.48-0.94
IFN-γ +874A/T A 130 [0.5856] 240 [0.5941] 0.8652 0.96 0.69-1.35
T 92 [0.4144] 164 [0.4059] 0.8652 1.03 0.74-1.44
TNF-α -238A/G A 41 [0.1847] 39 [0.0965] 0.0025 2.12 1.32-3.40
G 181 [0.8153] 365 [0.9035] 0.0025 0.47 0.29-0.76
TNF-α -308A/G A 30 [0.1351] 32 [0.0792] 0.0351 1.82 1.07-3.08
G 192 [0.8649] 372 [0.9208] 0.0351 0.55 0.32-0.93
Table 4. Distribution of the allele frequencies of polymorphisms of the IL-18 (-607 C/A and -137 C/G), IFN-γ (+874
A/T), and TNF-α (-238 A/G e -308 A/G) genes among patients with hepatocellular carcinoma (HCC) and healthy
controls.
When the -607C/A SNP of IL-18 was evaluated in terms of the different presentations of the
HCC, the frequencies of the -607*C and -607*A alleles between individuals with multinodular
and uninodular HCC, showed that the -607*C allele confers significant susceptibility to
multinodular lesions (P=0.0289; OR=2.4; 95%CI = 1.09-5.28). Evaluation of the genotype
frequency in SNP -607C/A of IL-18 revealed that genotype 607CC was significantly more
frequent in cases of multinodular HCC compared to uninodular tumors (P=0.0284; OR=3.5;
95%CI=1.24-9.86). On the other hand, genotype +874AT was found to be more frequent among
patients with infiltrative diffuse HCC compared to uninodular HCC (P=0.0443; OR=3.6;
95%CI=1.04-12.47), thus conferring greater susceptibility to the diffuse tumor.
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SNP Genotype frequency
genotype HCCn (frequency)
Control
n (frequency) P OR 95%CI
IL-18 -137C/G CG 48 [0.4286] 84 [0.4185] 0.9051 1.05 0.66-1.68
CC 7 [0.0625] 18 [0.0891] 0.5157 0.68 0.27-0.68
GG 57 [0.5089] 100 [0.4950] 0.9063 1.06 0.67-1.68
IL-18 -607A/C CA 56 [0.5000] 105 [0.5198] 0.8138 0.92 0.58-1.47
AA 18 [0.1607] 12 [0.0594] 0.0048 3.03 1.40-6.55
CC 38 [0.3393] 85 [0.4208] 0.1845 0.71 0.44-1.14
IFN-γ +874A/T AT 50 [0.4505] 82 [0.4059] 0.4741 1.20 0.75-1.91
AA 40 [0.3604] 79 [0.3911] 0.6276 0.88 0.54-1.42
TT 21 [0.1892] 41 [0.2030] 0.8823 0.92 0.91-1.65
TNF-α -238A/G GA 41 [0.3694] 39 [0.1931] 0.0011 2.44 1.45-4.12
AA 0 [0.0000] 0 [0.0000] 1.0000 1.81 0.03-92.15
GG 70 [0.6306] 163 [0.8069] 0.0011 0.40 0.24-0.69
TNF-α -308A/G GA 30 [0.2703] 26 [0.1287] 0.0031 2.51 1.39-4.51
AA 0 [0.0000] 3 [0.0149] 0.5548 0.25 0.01-4.99
GG 81 [0.7297] 173 [0.8564] 0.0098 0.45 0.25-0.80
Table 5. Distribution of the genotype frequencies of polymorphisms of the IL-18 (-607 C/A and -137 C/G), IFN-γ (+874
A/T), and TNF-α (-238 A/G and -308 A/G) genes among patients with hepatocellular carcinoma (HCC) and healthy
controls.
No significant differences in the allele or genotype frequencies of SNPs of IL-18, IFN-γ and
TNF-α were detected between the various tumor sizes, although the TNF-α -238*A allele was
slightly more frequent in tumors larger than 10cm compared to tumors smaller than 5cm
(P=0.0889; OR=2.82; 95%CI: 0.94-8.41). Similarly, genotype TNF-α -238AG indicated a margin‐
ally greater susceptibility to tumors >10cm (P=0.0565; OR=4.63; 95%CI=1.05-20.48) than to
tumors < 5 cm, whereas genotype TNF-α -238GG conferred marginal protection against large
lesions (>10 cm vs. <5cm) (P=0.0565; OR=0.22; 95%CI=0.05-0.95).
Evaluation of SNP -607C/A of IL-18 revealed no significant difference in allele and genotype
frequencies between patients with HCC with or without metastasis. In contrast, evaluation of
SNP -137C/G of IL-18 revealed that the -137*C allele was more frequent among individuals
with metastasis than among individuals with no meatastasis (P=0.0240; OR=4.00;
95%CI=1.32-12.14). The frequencies of genotypes -137CC, CG or GG did not differ significantly
between patients with and without metastasis, although genotype -137CC tended to confer
greater susceptibility to metastasis (P=0.0564; OR=8.80; 95%CI=1.29-60.13) and genotype
-137GG presented marginal protection against secondary lesions (P=0.0548; OR=0.14;
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95%CI=0.02-1.21). Regarding genes IFN-γ and TNF-α, the allele and genotype frequencies did
not differ significantly between the groups with and without metastasis.
The 14bp*D allele in gene HLA-G was more frequent in cases of HCC compared to control,
with the 14bp DD genotype tending to be more frequent among individuals with HCC. The
alleles and genotypes of the 14bp insertion/deletion polymorphism of the HLA-G were not
associated with disease severity.
Chen et al., in a study of 150 individuals of the Chinese Han population, showed that genotypes
of the 14bp insertion/deletion polymorphism of HLA-G were significantly associated with the
expression of soluble HLA-G in plasma in this population [35]. These authors detected a
dramatically lower expression of soluble HLA-G in plasma in the presence of the 14 bp I/I
genotype than in the presence of the 14 bp I/D (P = 0.004) or D/D (P = 0.003) genotypes. No
significant difference in plasma expression of soluble HLA-G was detected between 14 bp I/D
and D/D genotypes.
Many mechanisms of tumor escape have been proposed in the literature, some of them local
and others systemic. Particularly important among them is the expression of immunomodu‐
latory molecules in the tumoral microbiota, as well as the expression of soluble suppressive
factors by the tumoral cells. HLA-G represents one of these immunomodulatory molecules,
playing an important role in the mechanisms of immunotolerance by the inhibition of the
activity of NK cells, cytotoxic T lymphocytes and antigen-presenting cells [9,36].
The 14bp insertion/deletion polymorphism in exon 8 of HLA-G (3´UTR of the transcript) has
been associated with the magnitude of protein production through the modulation of the
stability of HLA-G mRNA, although the mechanisms involved still need to be elucidated. It
has been demonstrated that the HLA-G allele containing the insertion polymorphism may
suffer an additional splicing stage, so that 92 bp are removed from the primary mRNA. Thus,
smaller HLA-G transcripts, without the 92 bp, are more stable than the complete mRNA forms.
The alternative splicing may also be related to the presence of other polymorphisms in linkage
disequilibrium with the 14bp insertion [8,10]. Overall, HLA-G expression may be modulated
by many actors including transcription factors (influenced by the 5´ polymorphisms of the
promoter region) and the rate of mRNA degradation or translation, highly influenced by
polymorphisms observed at 3´UTR [8]. Ferguson et al. recently reported that the risk for
invasive cancer of the uterine cervix in a Canadian population was significantly higher in the
presence of 14 bp I/I genotype (OR=2.17, 95% CI: 1.10-4.27, P=0.020) as well as homozygous
genotypes HLA-G*01:01:02 (OR=3.52, 95% CI: 1.43-8.61, P=0.006) and *01:06 (OR=19.1, 95% CI:
2.29-159, P=0.005) [12]. Similarly, Chen et al. studying the relationship between HLA-G gene
polymorphism and the susceptibility of esophageal cancer in Kazakh and Han nationality in
Xinjiang, found that the risk of developing esophageal cancer was significantly increased in
individuals with 14 bp I/I genotype compared with 14 bp D/D genotype (OR=2.69, 95% CI:
1.30-5.55, P=0.04) in Kazakh population [11].
The tumoral microbiota or even the cells that underwent mutation per se can induce the
expression of HLA-G. Studies have demonstrated the expression of HLA-G in various
malignant tumors, although with variations in the percentage of lesions expressing the
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molecule. In studies involving renal cell carcinoma [37], endometrial adenocarcinoma [38] and
gastric cancer [39], at least 30% of the tumors exhibited HLA-G expression.
Regarding hepatic diseases, Souto et al., in a study of 74 liver biopsies of individuals with
chronic HBV infection and 10 specimens obtained from previously healthy cadaver liver
donors, demonstrated that 77% of the samples of chronic HBV hepatitis presented HLA-G
expression in the hepatocytes, as opposed to none of the controls [40]. These authors detected
a case of HCC, in which HLA-G expression was not detected in the tumor cells but was detected
in adjacent non-tumoral hepatic tissue.
Lin et al. evaluated by immunohistochemistry the expression of HLA-G in 219 HCC and
adjacent nontumoral tissue samples. The expression of HLA-G was observed in 50.2% of HCC
samples vs. 0% of normal corresponding adjacent tissue. Evaluation of HCC stages showed
that HLA-G expression was detected in 37.8%, 41.9% and 71.4% of cases in stages I, II and III,
respectively. The data reported by these authors revealed that the expression of HLA-G was
strongly correlated with advanced HCC stage and that soluble HLA-G was significantly more
elevated in the plasma of patients with HCC compared to healthy controls [41]. Similarly, Cai
et al. studied the expression of HLA-G by immunohistochemistry in 173 HCC specimens and
observed that HLA-G expression was associated with the prognosis of HCC, especially in the
early stages of the disease, with higher HLA-G expression being independently associated
with shorter overall survival and greater tumor recurrence after surgical resection [42].
Recently, a study involving 267 patients divided as anti-HBs positive healthy individuals
(n=50), chronic HBV carriers (n=45), active hepatitis B (n=46), liver cirrhosis (n=46) and early-
stage HCC patients (n=80) showed that serum concentrations of soluble human leukocyte
antigen-G (sHLA-G) were significantly higher in the active hepatitis B and HCC groups
compared to the other groups (P<0.05). Moreover, the concentrations of sHLA-G were higher
in the patients with HCC than in those with liver cirrhosis or active hepatitis B, suggesting that
serum sHLA-G concentrations may be associated with the different phases of hepatitis B
infection. They did not find any association between sHLA-G concentrations and HCC stage,
number of tumors, pathologic grade and presence of vascular invasion [43]. Another study,
examining fifteen SNPs in the non-classical class I alleles, found that the SNPs rs17875380,
rs41557518, rs114465251, and rs115492845 were associated with susceptibility to chronic
hepatitis B infection or HCC, and HLA-F*01:04, HLA-G*01:05N, and HLA-E*01:01 were
associated with hepatitis B or hepatitis B with HCC, concluding that these polymorphisms
may play an important role in immune surveillance of hepatitis B and HCC, possibly leading
to immune responses to virus or cancer cells [14].
It has been demonstrated that, in addition to genetic factors, the microbiota, for example, strees
inducers, hypoxia and cytokines (interferons, IL-10, TNF-α), influences the expression of HLA-
G, so that more studies are needed for a better understanding of the interaction of molecules
derived from the tumor and from host factors [9].
In summary, the present findings show that the deletion allele of the HLA-G 14bp insertion/
deletion polymorphism was more frequent among patients with tumors than among healthy
individuals, a fact that may confer greater susceptibility to HCC.
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A higher frequency of the IL-18 -607*A allele and -607AA genotype was found among HCC
patients compared to healthy individuals in the present study. Mi et al. analyzed a pool of
studies on the association between polymorphisms of the IL-18 gene and the risk of cancer
(cancer of renal cells, of the ovary and breast, nasopharyngeal an cervical cancer, cancer of the
esophagus, prostate, lung and stomach, and colorectal cancer) involving approximately 2137
cases and 3117 controls for the -607C/A variant, and 2372 cases and 3476 controls for the -137G/
C polymorphism, and they observed that the -607*A and -137*C alleles were associated with
an increased global risk of cancer compared to patients with the wild allele. Analysis of the
different ethnic groups showed that these polymorphisms were associated with an increased
risk of cancer in Asians but not in Europeans or Africans [44]. Regarding the evaluation of SNP
-137C/G, in the present study no significant differences in allele or genotype frequencies were
detected between patients with HCC and healthy individuals. However, the IL18 -137G/-607A
haplotype was more frequent among individuals with HCC than among control. These results
suggest that, even though no association was detected between SNP -137G/C and HCC, the
interaction between the two polymorphisms may have been involved in the susceptibility to
HCC. Regarding the polymorphism of the IFN-γ gene (+874 A/T), no significant difference in
allele or genotype frequencies were observed between patients with HCC and healthy controls.
Migita et al. studied 236 Japanese patients with chronic HBV infection who were divided into
two groups: with (n=48) and without (n=188) HCC, for the evaluation of the association of
polymorphisms of the TNF-α, IFN-γ, TGF-β1, IL-6 and IL-10 genes with the risk of HCC. When
evaluating the SNP +874 of IFN-γ, the authors did not detect a statistically significant difference
between the two groups, as also observed in the present study [45].
We observed that alleles TNF-α -238*A and -308*A confer significant susceptibility to HCC,
and that genotypes TNF-α -238GA and -308GA and haplotypes TNF-α -238A/-308G and
-238G/-308A are also more frequent among patients with HCC compared to control. Also in
agreement with these results, Akkiz et al. when analyzing 110 patients with HCC and 110
healthy controls from the Turkish population, observed that patients with HCC had a higher
frequency of genotype TNF-α -308GA and a lower frequency of genotype TNF-α -308GG
compared to control and after logistic regression, genotype -308GA was found to be associated
with risk of HCC. In addition, individuals with the -308*A allele (genotypes -308AA and
-308GA) had a 4.75-fold higher chance to develop HCC compared to individuals with the GG
genotype [46]. Similarly, Jung et al., studying 227 Korean patients with HCC and 365 controls,
detected a higher frequency of allele -238*A among patients with HCC than among healthy
controls [47]. On the other hand, Yang et al., did not find statistical difference in TNF-α -308G/
A alleles or genotypes frequencies between Chinese HCC patients (n=772) and healthy controls
(n=852), but they observed that TNF-α -863AA genotype may increase the risk of HCC
compared with the wild-type TNF-α CC [48].
The expression of TNF-α is regulated both at the transcriptional and post-transcriptional level
and polymorphisms in the promoter region of TNF-α have been related to the production of
this cytokine [22]. Greater TNF-α production up to five-fold the basal level and induction of
mRNA expression have been associated with the TNF-α -308*A allele, with elevated serum
TNF levels being observed even in heterozygous patients [49]. Many mechanisms of the
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cancerigenous activity of TNF-α have been suggested, such as induction of pro-malignant
chemokines, metalloproteinases, cell adhesion molecules, angiogenic mediators, reactive
oxygen intermediates and inflammatory enzymes. Increased TNF-α levels are correlated with
hepatic inflammation, fibrosis and tissue damage [46].
Studies evaluating the association of polymorphisms of IL-18 with the severity of cancer have
been reported. Saenz-Lopez et al. investigated whether the presence of SNPs -137G/C and
-607A/C of IL-18 were associated with size, grade, and TNM Classification of 158 patients with
renal cell carcinoma. These authors observed that genotype -607CC was significantly associ‐
ated with larger tumor size (P=0.001), grade (P=0.030), and T (P=0.001) and M (P=0.012) stage,
while genotype -137GG was correlated with larger tumor size (P=0.036), grade (P=0.017), and
stage T (P=0.026) [50]. Another authors, studing the association of SNPs -607A/C and -137G/C
of IL-18 with histology of colorectal and gastric cancer (moderately differentiated or undiffer‐
entiated vs. well differentiated), noticed that no difference in genotype frequency was detected,
although the combination of genotypes -607AA/-137GC was more frequent among patients
with less differentiated tumors [51].
Literature evidence has demonstrated that IL-18 is a pleiotropic cytokine that enhances the
Th1 or Th2 immune response according to the medium and to genetics. In the presence of
IL-12, IL-18 induces IFN-γ secretion by NK and T cells, activating the Th1 response, important
for defense against tumor cells. On the other hand, IL-18 can increase tumor growth via
increased stimulation of VEGF and of the immune response, and also stimulate solid tumor
metastasis [52]. A possible explanation for this fact is the increased Th1 response in the early
stages of the cancer which, however, is replaced with Th2 as tumor malignancy worsens with
tumor development. Thus, as the tumor develops, IL-18 polymorphisms, which induce great
IL-18 production, may contribute to the promotion of more advanced tumors due to the
activation of angiogenesis, differentiation of tumor cells and regulation of stimulators of cell
proliferation [53]. To corroborate these data, Tangkijvanich et al., in a study of 70 patients with
HCC and 10 healthy controls, observed that serum IL-18 levels were significantly correlated
with the presence of vascular invasion and of more advanced tumors according to the Okuda
classification. In addition, the survival of patients with high serum levels of IL-18 was worse.
Multivariate analysis showed that serum IL-18 levels proved to be a significant and inde‐
pendent prognostic factor regarding survival [54].
Regarding the +874 A/T polymorphism of the IFN-γ gene, study involving 100 patients with
chronic HCV infection and different degrees of disease severity (chronic hepatitis, n=42;
cirrhosis + HCC, n=58) and 103 healthy controls detected that the TT and AT genotypes were
significantly more frequent among patients with cirrhosis and HCC. These genotypes were
associated with a 2.5 higher risk of progression to more severe forms of hepatic disease. In
addition, the +874*T allele was approximately twice more frequent among patients in an
advanced stage of hepatitis C than among patients with chronic hepatitis, although multivari‐
able analysis did not show that the +874*T allele was an independent predictive factor of
severity [55].
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5. Conclusions
Our results suggest that the 14bp-deletion allele in HLA-G gene is associated with HCC
susceptibility in a Brazilian population, and that the alleles IL-18 -607*A and TNF-α (-238*A
and -308*A) may confer susceptibility to HCC, whereas IL-18 -607*C and -137*C alleles may
confer susceptibility to multinodular and diffuse HCC, respectively. Furthermore, deletion/
deletion genotype was marginally associated with greater risk of HCC. More studies in
different populations are needed to confirm these findings.
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